Literature DB >> 6607221

Experimental beryllium-induced lung disease. II. Analyses of bronchial lavage cells in strains 2 and 13 guinea pigs.

B P Barna, S D Deodhar, S Gautam, M Edinger, T Chiang, J T McMahon.   

Abstract

In previous studies, we found that endotracheal administration of beryllium oxide (BeO) produced cell-mediated immunity and granulomatous lung disease in strain 2 but not strain 13 guinea pigs. This report describes phenotypic and functional studies of bronchial lavage cells from both guinea pig strains after BeO exposure. In BeO-treated strain 2 animals, the percentage of T (ER+)3 lymphocytes was significantly (p less than 0.05) elevated above normal by 2 weeks after BeO exposure, while T lymphocytes were not increased in strain 13. Giant cells containing crystalline material in fused, coalesced phagolysosomes were observed in treated animals of both strains. BeO-exposed strain 2 alveolar macrophages (AM) demonstrated enhanced killing of Listeria monocytogenes and enhanced chemiluminescence, while AM of strain 13 had responses below controls. Findings support the presence of BeO-induced cellular immunologic activity in strain 2 animals and, on the other hand, suggest BeO toxicity to lavage cells in strain 13.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6607221

Source DB:  PubMed          Journal:  Int Arch Allergy Appl Immunol        ISSN: 0020-5915


  3 in total

1.  Studies on the adjuvant action of beryllium. IV. The preparation of beryllium containing macromolecules that induce immunoblast responses in vivo.

Authors:  J G Hall
Journal:  Immunology       Date:  1988-06       Impact factor: 7.397

2.  Granulomatous disease associated with pulmonary deposition of titanium.

Authors:  S Redline; B P Barna; J F Tomashefski; J L Abraham
Journal:  Br J Ind Med       Date:  1986-10

3.  Animal models of beryllium-induced lung disease.

Authors:  G L Finch; M D Hoover; F F Hahn; K J Nikula; S A Belinsky; P J Haley; W C Griffith
Journal:  Environ Health Perspect       Date:  1996-10       Impact factor: 9.031

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.